Skin & Collagen
Research compounds studied for collagen synthesis, skin elasticity, wound healing, and photoprotection. Many available topically - no injection required for entry-level use.
Most researched for Skin & Collagen
GHK-Cu
The most extensively researched skin peptide with decades of published data. A naturally occurring copper-binding tripeptide that activates collagen and elastin gene expression. Unique because it is effective both topically (as a serum) and systemically (injected). Research shows activation of over 4,000 genes related to tissue remodeling and anti-aging. The most accessible entry point with the strongest evidence base.
Acetyl Tetrapeptide-9
aka Collalift, Dermican
Acetyl Tetrapeptide-9 is a synthetic topical cosmetic peptide marketed as Collalift. In laboratory testing it has been reported to stimulate synthesis of lumican, a small proteoglycan that helps organize collagen fibers in the dermis. It is formulated into anti-aging and firming skincare products. Published evidence rests largely on laboratory and manufacturer studies rather than independent clinical trials.
How it works: It is reported to stimulate lumican, a collagen-organizing proteoglycan, supporting dermal matrix structure in laboratory studies.
Anti-aging serums; firming creams; eye creams; dermal density support
Research dose
3-6 % (topical), 1–2×/day
Real-world (reported)
3–6% in serum/cream. Combine with Matrixyl.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Used by sophisticated formulators targeting skin structural improvement beyond just collagen quantity.
- Onset
- Firmness 4–8 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Rare side effects
- No serious adverse effects
- Contraindications
- Known sensitivity
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- Matrixyl: collagen synthesis complement (synthesis + organization). Hexapeptide-10: DEJ support.
- Secondary uses
- ECM remodeling; skin structure improvement
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
- Typical price
- $10–$50 / ingredient
- Research evidence
- Cell or lab studies only
- Chemical data
- CAS 928006-50-2 · C22H33N7O9 · 539.5
Collagen Peptides
aka Hydrolyzed collagen, collagen hydrolysate, Peptan
Collagen peptides are hydrolyzed collagen fragments sold as an oral supplement under names such as Peptan. Ingested peptides are absorbed and may act as signaling molecules that stimulate fibroblast activity and matrix production. Randomized trials and meta-analyses report improvements in skin hydration and elasticity, although study quality and industry funding vary considerably.
How it works: Hydrolyzed collagen fragments are absorbed and may signal fibroblasts to increase collagen and extracellular matrix synthesis.
Skin hydration; skin elasticity; nail and hair support; joint and bone research
Research dose
5-15 g, Once daily
Real-world (reported)
10g/day oral. Take with 200mg Vitamin C.
Administration
Oral
Timing
Any time
Cycle length
12 wks (skin); 24 wks (joints)
Real-world figures are community-reported, not medical advice.
Common side effects: Mild gastrointestinal discomfort; fullness; aftertaste
Community take: [ANECDOTAL] Well-established supplement with good RCT base. 10g/day minimum; bovine or marine; 12+ weeks. Vitamin C co-administration important.
- Onset
- Skin 4–8 wks; joint 12–24 wks; bone months
- Half-life
- Not established
- Storage
- Dry: Room temperature; dry
- Reconstitution
- N/A (food/supplement)
- Rare side effects
- No serious effects; long safety record as food supplement
- Contraindications
- Animal-derived hypersensitivity (bovine/marine/porcine)
- Drug interactions
- No significant interactions
- Recommended bloodwork
- Optional PINP/P1NP (bone collagen marker)
- Stacks well with
- GHK-Cu topical: systemic (oral) + local (topical) collagen synergy. Vitamin C: essential co-factor.
- Secondary uses
- Bone density; muscle mass (adjunct); hair and nails; wound healing
- Legal status
- US: Dietary supplement (FDA 21 CFR) · UK: Dietary supplement / food ingredient · Canada: NHP (Natural Health Product) · Australia: TGA-listed therapeutic / food · EU: Food supplement; member state level
- Typical price
- $20–$60 / month supply
- Research evidence
- Human trials - early or small
Leuphasyl
aka Pentapeptide-18
Leuphasyl is the trade name for pentapeptide-18, a synthetic peptide related to the natural opioid peptide leu-enkephalin. It is used in topical cosmetic products, sometimes alongside other peptides, and is marketed to soften the appearance of expression lines. Its cosmetic activity is supported mainly by manufacturer and laboratory data. It is regulated as a cosmetic ingredient.
How it works: It acts as an enkephalin-like ligand at neuronal receptors and is proposed to modulate the signaling that drives muscle contraction.
Expression lines; forehead wrinkles; combination formulations; cosmetic anti-aging
Research dose
2-5 % (topical), 1–2×/day
Real-world (reported)
3–5% serum; combine with Argireline.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Less well known than Argireline but additive. Formulators combine 3–5% each.
- Onset
- 4–8 wks expression wrinkle reduction
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Rare side effects
- No serious adverse effects
- Contraindications
- Known sensitivity
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- Argireline: additive effect demonstrated. Syn-Ake: NMJ modulator complement.
- Secondary uses
- Crow's feet; frown lines; forehead
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
- Typical price
- $10–$40 / ingredient
- Research evidence
- Minimal published research
- Chemical data
- CAS 64963-01-5 · C29H39N5O7 · 569.6
Palmitoyl Tripeptide-1
aka Pal-GHK, Biopeptide EL, Biopeptide CL
Palmitoyl Tripeptide-1 is a synthetic lipopeptide consisting of a glycine-histidine-lysine sequence linked to a palmitic acid chain that improves skin penetration. It is used in topical cosmetic products, often within combination formulations, and is marketed to support the appearance of firmer skin. In laboratory studies it has been reported to stimulate fibroblast activity and matrix components. It is regulated as a cosmetic ingredient.
How it works: It is proposed to signal dermal fibroblasts to increase production of collagen and glycosaminoglycans.
Skin firmness; fine line appearance; combination formulations; cosmetic anti-aging
Research dose
2-8 % (topical), 1–2×/day
Real-world (reported)
3–8% in serum/cream daily.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Classic collagen peptide. Frequently combined with Matrixyl 3000 in commercial formulations.
- Onset
- Collagen changes 4–12 wks; firmness 8 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Rare side effects
- No serious adverse effects
- Contraindications
- Known sensitivity
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- Palmitoyl Pentapeptide-4 (Matrixyl): additive collagen stimulation. GHK-Cu injectable: injectable complement.
- Secondary uses
- Fibronectin; skin texture
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
- Typical price
- $5–$40 / product
- Research evidence
- Cell or lab studies only
- Chemical data
- CAS 147732-56-7 · C30H54N6O5 · 578.8
Syn-Ake
aka Dipeptide Diaminobutyroyl Benzylamide Diacetate
Syn-Ake is the trade name for a synthetic peptide modeled on waglerin-1, a component of temple viper venom. It is used in topical cosmetic products marketed to relax facial muscle movement and soften the look of expression lines. Reported activity comes largely from laboratory and manufacturer data rather than independent peer-reviewed clinical trials. It is regulated as a cosmetic ingredient.
How it works: It is designed to act as an antagonist at muscle nicotinic acetylcholine receptors, reducing muscle contraction linked to expression lines.
Expression lines; forehead wrinkles; facial muscle relaxation; cosmetic anti-aging
Research dose
2-4 % (topical), 1–2×/day
Real-world (reported)
2–4% serum on expression lines 1–2×/day.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] 2–4% noticeable wrinkle reduction. Different mechanism from Argireline so additive when combined.
- Onset
- Expression wrinkle reduction 4–8 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Reconstitution
- N/A (pre-formulated)
- Rare side effects
- No serious adverse effects at cosmetic concentrations
- Contraindications
- Known sensitivity
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- Argireline: complementary SNARE mechanism (additive). Snap-8: additional SNARE complement.
- Secondary uses
- Skin smoothing; anti-aging
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
- Typical price
- $10–$60 / cosmetic product
- Research evidence
- Minimal published research
- Chemical data
- CAS 823202-99-9 · C23H37N5O7 · 495.6
Hexapeptide-10
aka Serilesine, SIKVAV
Hexapeptide-10, sold as Serilesine, is a synthetic cosmetic peptide that mimics an adhesion fragment of the laminin protein. In laboratory studies it promotes skin cell adhesion and proliferation and supports the junction between the epidermis and dermis. It is used in topical firming and anti-aging formulations. Independent clinical evidence in cosmetics is limited.
How it works: It is a laminin-derived peptide that promotes keratinocyte and fibroblast adhesion and reinforces the dermo-epidermal junction.
Firming skincare; anti-aging serums; skin density; dermo-epidermal support
Research dose
2-5 % (topical), 1–2×/day
Real-world (reported)
3–5% serum. Combine with Matrixyl.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Less mainstream than Matrixyl but valued for DEJ support in premium formulations.
- Onset
- Firmness 4–12 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Rare side effects
- No serious adverse effects
- Contraindications
- Known sensitivity
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- Matrixyl: collagen complement. GHK-Cu: comprehensive anti-aging skin stack.
- Secondary uses
- Hair follicle anchoring (niche)
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
- Typical price
- $10–$50 / ingredient
- Research evidence
- Cell or lab studies only
- Chemical data
- CAS 146439-94-3 · C28H53N7O8 · 615.8
Key risk: Laboratory findings that its core sequence can promote blood vessel growth and tumor progression warrant caution, though the relevance to topical use is not established.
Matrixyl
aka Palmitoyl Pentapeptide-4, Pal-KTTKS, Palmitoyl Pentapeptide-3
Matrixyl is the trade name for palmitoyl pentapeptide-4, a synthetic lipopeptide that joins a fragment of type I procollagen to a palmitic acid chain that aids skin penetration. It is used in topical cosmetic products marketed for the appearance of fine lines and photoaged skin. A small controlled clinical study reported improved wrinkle appearance and good skin tolerability. It is regulated as a cosmetic ingredient rather than a drug.
How it works: It acts as a matrikine signal proposed to prompt dermal fibroblasts to increase synthesis of collagen and other matrix proteins.
Fine line appearance; photoaged skin; skin firmness; cosmetic anti-aging
Research dose
2-8 % (topical), 1–2×/day
Real-world (reported)
2–8% in serum or cream applied daily. Often combined with GHK-Cu and/or Argireline.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL – skincare community] One of most researched cosmetic peptides. Widely used in anti-aging serums. Clinical studies demonstrate measurable collagen increase.
- Onset
- Collagen changes 4–12 wks; skin firmness 8 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge; follow label
- Rare side effects
- No serious adverse effects documented
- Contraindications
- Known ingredient sensitivity; Known hypersensitivity to palmitoyl pentapeptide-4 or related cosmetic peptide i; Use on broken; wounded; or severely compromised skin should be avoided unless sp; No significant interactions with other topical skincare ingredients have been id
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- GHK-Cu: additive collagen stimulation. Palmitoyl Tripeptide-1: complementary collagen pathway.
- Secondary uses
- ECM remodeling; skin hydration; anti-aging
- Legal status
- Approved
- Typical price
- $5–$40 / product
- Research evidence
- Human trials - early or small
- Indications
- Anti-aging skincare (wrinkle and fine line reduction); Collagen stimulation in photoaged skin; Cosmetic formulation active ingredient
- Chemical data
- CAS 214047-00-4 · C39H75N7O10 · 802.05 Da
- Amino acids
- 41 aa
Snap-8
aka Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-1
Snap-8, known by the cosmetic ingredient names Acetyl Octapeptide-3 and Acetyl Glutamyl Heptapeptide-1, is a topical peptide used in anti-wrinkle skincare. It is a fragment that mimics part of the SNAP-25 protein and is proposed to interfere with the SNARE complex that drives neurotransmitter release, so facial muscle contraction is reduced. It is studied mainly for softening expression lines on the forehead and around the eyes.
How it works: It mimics part of the SNAP-25 protein and interferes with the SNARE complex, reducing the neurotransmitter release that triggers muscle contraction.
Expression line reduction; anti-wrinkle skincare; topical cosmetic formulation
Research dose
3-8 % (topical), 1–2×/day
Real-world (reported)
3–8% in serum formulation. Used alongside Argireline for additive effect.
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL – skincare community] Preferred over Argireline by some formulators for potentially stronger effect at lower concentration. DIY cosmetics use common.
- Onset
- Expression wrinkle reduction 4–8 wks
- Half-life
- Not established
- Storage
- Dry: Room temp or fridge
- Reconstitution
- N/A (pre-formulated)
- Rare side effects
- No serious adverse effects
- Contraindications
- Known ingredient sensitivity; Known hypersensitivity to SNAP-8 or related peptide ingredients; Active skin infections or open wounds at application site; Severe inflammatory skin conditions at application siteFrequency distribution of; No significant drug interactions reported for topical SNAP-8
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- GHK-Cu: collagen synergy. Argireline: similar mechanism (often combined).
- Secondary uses
- Forehead lines; eye wrinkles; facial rejuvenation
- Legal status
- Preclinical Research
- Typical price
- $10–$40 / raw ingredient; $20–$60 / commercial serum
- Research evidence
- Minimal published research
- Indications
- Anti-wrinkle and anti-aging cosmeceutical research; Topical neuromuscular junction modulation studies; SNARE complex inhibition research; Cosmetic peptide formulation development
- Chemical data
- CAS 868844-74-0 · C41H70N16O16S · 1075.16 Da
- Amino acids
- 215 aa
Argireline
aka Acetyl Hexapeptide-3, Acetyl Hexapeptide-8
Argireline is the trade name for acetyl hexapeptide, a synthetic peptide whose sequence corresponds to the end of the SNAP-25 protein involved in neurotransmitter release. It is used in topical cosmetic products intended to soften the appearance of expression lines. A 2002 study reported reduced wrinkle depth with a topical formulation, although independent clinical evidence remains limited. It is regulated as a cosmetic ingredient.
How it works: It mimics the SNAP-25 protein terminus and is proposed to interfere with SNARE complex formation, reducing muscle contraction.
Expression lines; forehead wrinkles; crow's feet appearance; cosmetic anti-aging
Research dose
5-10 % (topical), 1–2×/day (topical serum/cream)
Real-world (reported)
5–10% serum applied to expression lines 1–2×/day. Leave 20 min before other skincare.
Administration
Topical (serum, cream, eye cream)
Timing
Morning and/or evening
Cycle length
Ongoing (cosmetic use)
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL – skincare community] Very popular in DIY skincare. At 5–10%, meaningful wrinkle reduction reported. 'Budget Botox.' Must stay on skin long enough to penetrate.
- Onset
- Expression wrinkle reduction 4–8 wks
- Half-life
- Not established
- Storage
- Dry: Room temperature or fridge; follow product label
- Reconstitution
- N/A (pre-formulated cosmetic)
- Rare side effects
- No serious adverse effects documented at cosmetic concentrations
- Contraindications
- Known sensitivity to any ingredient; Known hypersensitivity to acetyl hexapeptide-8 or any formulation components; Should not be used as a substitute for medical treatment of neuromuscular disord; No significant interactions with other topical skincare ingredients. Compatible
- Drug interactions
- No significant interactions at cosmetic use
- Recommended bloodwork
- None required for cosmetic topical use
- Stacks well with
- GHK-Cu: synergistic collagen + wrinkle combo. Snap-8: similar mechanism, additive.
- Secondary uses
- Skin smoothing; anti-aging
- Legal status
- Preclinical Research
- Typical price
- $5–$30 / cosmetic serum
- Research evidence
- Human trials - early or small
- Indications
- Dynamic wrinkle reduction (forehead lines, crow's feet, frown lines); Anti-aging cosmetic formulations; Non-invasive alternative to botulinum toxin injections
- Chemical data
- CAS 616204-22-9 · C34H60N14O12S · 889 Da
- Amino acids
- 46 aa
OS-01
aka Peptide 14, Decapeptide-52, OneSkin peptide
OS-01 is a synthetic ten amino acid peptide developed by OneSkin and assigned the cosmetic name Decapeptide-52. It is described as a topical senotherapeutic intended to reduce markers of cellular senescence in skin. A twelve-week split-face, vehicle-controlled study reported reduced water loss and improved wrinkle appearance and texture. It is marketed as a cosmetic rather than a drug, and independent replication remains limited.
How it works: It is proposed to act as a senotherapeutic, reducing accumulation of senescent cells and their inflammatory secretions in skin.
Skin rejuvenation; wrinkle reduction; barrier support; senescence reduction
Administration
Topical
Timing
Apply to clean skin before moisturizer; morning and evening
Cycle length
Ongoing (minimum 8-12 weeks for results)Step-wise Titration
Common side effects: Not established
- Half-life
- Not established
- Contraindications
- Known allergy to any component of the OneSkin formulation; Open wounds or severely damaged skin (not studied in this population)Frequency d; No drug interactions have been formally studied for topical OS-01 formulations👥
- Legal status
- Preclinical Research
- Research evidence
- Human trials - early or small
- Indications
- Topical skin rejuvenation (cosmetic product); Skin barrier function improvement; Reduction of visible signs of skin aging
- Amino acids
- 10 aa
GHK-Cu Topical Serum
This entry describes glycyl-L-histidyl-L-lysine copper as a topical serum presentation. It is the same molecule as the existing GHK-Cu row and differs only by presentation. GHK-Cu is a copper-binding tripeptide studied for effects on collagen synthesis, matrix remodeling, and wound repair, used mainly as a topical cosmetic ingredient.
How it works: It carries copper into tissue and acts as a signaling molecule that modulates genes linked to matrix remodeling and repair.
Skin anti-aging; collagen support; wound healing research; hair research
Research dose
0.05-1 % (topical), 1–2×/day
Real-world (reported)
0.1–0.5% serum daily. Scalp 0.1% for hair. Do NOT use same session as Vitamin C (oxidation).
Administration
Topical
Timing
Morning and/or evening
Cycle length
Ongoing
Real-world figures are community-reported, not medical advice.
Common side effects: Local skin irritation; redness; itching
Community take: Preclinical research demonstrates synergistic benefit when GHK-Cu is combined with Torilis japonica extract at a 4:6 ratio, showing simultaneous anti-inflammatory, antioxidant, and regenerative effects with no cell viability compromise.
- Onset
- Skin 4–12 wks; scar months
- Half-life
- Not established
- Storage
- Dry: Fridge preferred; room temp ≤3 mo; light sensitive
- Reconstitution
- N/A (pre-formulated)
- Rare side effects
- No serious effects at cosmetic concentrations
- Contraindications
- Known copper allergy; Wilson's disease
- Drug interactions
- No cosmetic interactions
- Recommended bloodwork
- None required
- Stacks well with
- GHK-Cu injectable: same compound different route. Argireline: expression wrinkle complement. Matrixyl: collagen synergy.
- Secondary uses
- Antioxidant support, wound healing
- Legal status
- US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: TGA cosmetic listed; injectable regulated separately · EU: Legal OTC cosmetic
- Typical price
- $10–$60 / serum
- Research evidence
- Human trials - early or small
Afamelanotide
aka Scenesse, Melanotan I, NDP-MSH
Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone that activates the melanocortin-1 receptor to increase protective eumelanin pigment in the skin. Marketed as the implant Scenesse, it is FDA approved to increase pain-free light exposure in adults with erythropoietic protoporphyria. It has also been researched for other light-sensitivity and pigmentation conditions such as vitiligo.
How it works: It binds and activates the melanocortin-1 receptor, stimulating protective eumelanin pigment production in the skin.
Erythropoietic protoporphyria; skin photoprotection; pigmentation disorders; vitiligo research
Administration
SC
Timing
Administered by certified healthcare provider as a bioresorbable implant above the anterior supra-iliac crest. Typically 5-6 implants per year.
Cycle length
Seasonal (spring through fall)
Common side effects: Implant site reactions; nausea; oropharyngeal pain; cough; fatigue
- Half-life
- Approximately 30 minutes
- Reconstitution
- Sterile water
- Contraindications
- Known hypersensitivity to afamelanotide or any component of the implant; Patients should not have unexamined suspicious melanocytic lesions prior to impl; No clinically significant drug interactions have been identified. Afamelanotide; Afamelanotide does not replace the need for sun protection measures. Patients sh
- Legal status
- Approved
- Research evidence
- Approved - large human trials
- Indications
- Erythropoietic protoporphyria (EPP) photoprotection (FDA/EMA approved); Vitiligo repigmentation (Phase 3 investigational)
- Chemical data
- CAS 75921-69-6 · C78H111N21O19 · 1647 Da
- Amino acids
- 260 aa
Key risk: Increased skin pigmentation may mask developing skin cancers, so periodic skin monitoring is recommended.
Melanotan II
aka MT-II, MT-2
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone that non-selectively activates several melanocortin receptors, including MC1 and MC4. Through MC1 it darkens skin by stimulating melanin, and through MC4 it can influence sexual arousal and appetite. It is not approved for any human use and is sold only as an unregulated research chemical, and it is a different molecule from afamelanotide, which is Melanotan I.
How it works: It non-selectively activates melanocortin receptors, increasing skin melanin through MC1 and affecting sexual function through MC4.
Skin tanning; erectile function; appetite research; melanocortin studies
Research dose
250-1000 mcg, Daily (loading) then maintenance 2–3×/week
Real-world (reported)
Start low 250 mcg; build to 500–1000 mcg. Evening dose to sleep through nausea. UV exposure needed for tanning effect.
Administration
SubQ
Timing
Evening (nausea management)
Cycle length
Loading 1–2 wks; maintenance ongoing (with UV exposure for tanning)
Real-world figures are community-reported, not medical advice.
Common side effects: Facial flushing; nausea and vomiting; appetite loss; spontaneous erections; darkening of moles
Community take: [ANECDOTAL] Very popular for tanning. 'Barbie drug' in media. Community concern about mole changes — dermatology visits recommended. Libido effect strong.
- Onset
- Tanning 2–4 wks with UV; libido hours
- Half-life
- Not established in humans
- Storage
- Dry: Fridge 2–8°C; freeze long-term; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 10 mg vial = 5 mg/mL; 500 mcg dose = 10 IU
- Rare side effects
- Darkening/enlargement of moles (melanoma risk concern); melanoma case reports; prolonged erection; hypertension; hyperpigmentation of normal skin
- Contraindications
- Personal or family history of melanoma; active malignancy; pregnancy; cardiovascular disease; PT-141 preferred for pure sexual health (fewer pigmentation concerns); Uncontrolled hypertension or significant cardiovascular disease; History or risk of priapism; Pregnancy and lactation; Severe renal impairment
- Drug interactions
- Antihypertensives (additive BP effects); sexual function medications
- Recommended bloodwork
- Dermatology check (mole mapping) before and every 6 months; BP monitoring
- Stacks well with
- PT-141 (more selective; no tanning — choose one or the other based on goal).
- Secondary uses
- Appetite suppression; fat loss (secondary)
- Legal status
- Preclinical Research
- Typical price
- $25–$60 / 10 mg vial
- Research evidence
- Human trials - early or small
- Indications
- Melanogenesis and tanning research; Melanocortin receptor pharmacology studies; Sexual function research (led to development of PT-141); Appetite regulation and energy homeostasis studies
- Chemical data
- CAS 121062-08-6 · C50H69N15O9 · 1024.18 Da
- Amino acids
- 243 aa
Key risk: It has been associated with new and darkening melanocytic moles and reported cases of melanoma.
Icotrokinra
aka Icotyde, JNJ-2113, JNJ-77242113
Icotrokinra is an orally administered peptide that selectively blocks the interleukin-23 receptor, interrupting a signaling pathway that drives the inflammation underlying plaque psoriasis. It is a once-daily pill and is notable as the first oral agent to target this receptor. The FDA approved it in March 2026 under the brand name Icotyde for adults and adolescents with moderate to severe plaque psoriasis.
How it works: It is a peptide antagonist that binds the interleukin-23 receptor, blocking IL-23 signaling that promotes inflammatory responses.
Plaque psoriasis; psoriatic disease; interleukin-23 mediated inflammation
Administration
Oral
Timing
Once-daily oral tablet; no specific timing relative to meals reported
Cycle length
OngoingStep-wise Titration
Common side effects: Headache; nausea; cough; fatigue; fungal infections
- Half-life
- Not established
- Storage
- Dry: Store at room temperature; protect from moisture and light
- Contraindications
- Known hypersensitivity to icotrokinra or any excipient; Active serious infections (consistent with immunomodulatory therapy guidelines)F; No clinically significant drug interactions have been identified in clinical tri; Live vaccines should be avoided during treatment, consistent with recomm
- Legal status
- Investigational
- Research evidence
- Approved - large human trials
- Indications
- Moderate-to-severe plaque psoriasis (adults and adolescents 12+); Scalp and genital psoriasis (high-impact sites); Ulcerative colitis (Phase 2b, under investigation)
- Chemical data
- CAS 2763602-16-8 · C90H120N20O22S2 · 1898.19 Da
- Amino acids
- 160 aa
Key risk: No boxed warning applies; tuberculosis screening is advised before starting treatment.
Botulinum Toxin
aka Botox, OnabotulinumtoxinA, BoNT-A
Botulinum toxin type A is a purified neurotoxin protein produced by Clostridium botulinum and marketed as Botox. It is FDA approved for a broad range of therapeutic uses, including chronic migraine, cervical dystonia, spasticity, overactive bladder, severe underarm sweating, and blepharospasm. It acts locally at the neuromuscular junction to inhibit acetylcholine release.
How it works: It cleaves SNARE proteins to inhibit acetylcholine release at the neuromuscular junction, producing local chemodenervation.
Chronic migraine; cervical dystonia; spasticity; overactive bladder; hyperhidrosis
Administration
IM
Timing
No specific time of day; administered in clinic by trained healthcare professional
Cycle length
Ongoing; repeated every 12 weeks as needed
Common side effects: Injection site pain or bruising; headache; neck pain; urinary tract infection; eyelid drooping
- Half-life
- Not established
- Storage
- Dry: Store unopened vials refrigerated at 2-8C (or frozen at or below -5C for some formulations). Reconstituted solution: store refrigerated and use within
- Reconstitution
- Sterile 0.9% salineUse within: 24 hours
- Contraindications
- Known hypersensitivity to botulinum toxin or any formulation component; Infection at the proposed injection site; Pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome,; Pregnancy and breastfeeding (Category C; insufficient data)Frequency distributio
- Legal status
- Approved
- Research evidence
- Approved - large human trials
- Indications
- Chronic migraine prophylaxis; Cervical dystonia; Upper and lower limb spasticity; Blepharospasm; Cosmetic treatment of facial wrinkles; Axillary hyperhidrosis; Overactive bladder
- Chemical data
- CAS 93384-43-1 · Complex protein · 149000 Da
- Amino acids
- 296 aa
Key risk: The toxin effect may spread from the injection site, and resulting swallowing and breathing difficulties can be life threatening, with reports of death.
Epitalon Oral
aka Oral Epitalon
This entry is an oral presentation of Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly modeled on a pineal preparation. It is the same molecule as the existing Epitalon row and is not a separate compound. Epitalon is studied for reported effects on melatonin, telomerase activity, and aging markers, largely in animal models and small human studies. Oral peptide bioavailability is generally low.
How it works: It is reported to influence pineal and neuroendocrine signaling and telomerase activity in preclinical work.
Longevity research; telomere biology; aging studies
Research dose
20-30 mg, Daily (oral)
Real-world (reported)
20–30 mg oral daily ×10–20 consecutive days. 2 cycles/year.
Administration
Oral
Timing
Morning
Cycle length
10–20 day course; 2× per year
Real-world figures are community-reported, not medical advice.
Common side effects: Not established
Community take: [ANECDOTAL] Many longevity users prefer oral for convenience vs injectable. Debate: injectable may have superior bioavailability. Community divided.
- Onset
- Sleep effects 1–2 wks; biomarker changes months
- Half-life
- Not established
- Storage
- Dry: Room temperature; dry
- Reconstitution
- N/A (pre-formulated)
- Rare side effects
- Same theoretical concerns as injectable; less studied than injectable
- Contraindications
- Active malignancy (theoretical); pregnancy
- Drug interactions
- No significant interactions
- Recommended bloodwork
- Melatonin; telomere length (research context)
- Stacks well with
- Thymalin: immune complement. GHK-Cu: tissue repair longevity stack.
- Secondary uses
- Oral convenience vs injectable; lower bioavailability debated
- Legal status
- US: Research use only; PCAC July 2026 · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $30–$60 / pack
- Research evidence
- Human trials - early or small
Example stacks
Skin & Collagen - Beginner
Topical GHK-Cu serum is the most accessible entry point - no injections, widely available, and decades of evidence behind it.
- • Apply to clean dry skin after cleansing
- • Use AM and PM consistently
- • Choose a serum with GHK-Cu listed as a primary active
Skin & Collagen - Intermediate
Systemic GHK-Cu via injection delivers peptide throughout the whole body. Combined with Epithalon it addresses skin aging from both structural and cellular angles.
- • Rotate injection sites for daily GHK-Cu
- • Take before and after photos at weeks 0, 4, 8, 12
- • Combine systemic with topical GHK-Cu
Community outcome data
Collected from users researching this goal. Not a clinical database - for general reference only.
Share your experience
Your experience helps others research this goal. All submissions are anonymous.
Ready to actually use this research?
FREETwo tools that turn this research into something you can actually use - no signup needed.
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.